C
Corner Therapeutics
Pioneering a new class of immunotherapies
About Corner Therapeutics
Corner Therapeutics is a pioneering biotech company focused on developing advanced immunotherapies to combat cancer and other diseases. The company operates in the biotechnology and healthcare market, targeting clients such as medical institutions, research organizations, and pharmaceutical companies. Corner Therapeutics' business model revolves around proprietary stimuli that induce a hyperactive state in dendritic cells, leading to the production of diverse, polyclonal populations of long-lived memory T cells. This approach aims to provide durable protective immunity, overcoming the limitations of traditional immunostimulants that fail to generate long-lasting immune responses. The company generates revenue through partnerships, licensing agreements, and the commercialization of its innovative therapies.
Key personnel include Sivan Elloul, Ph.D., Vice President of Research and Development, who brings extensive experience in cancer biology and immunotherapy. The company is committed to fostering a dynamic workplace with significant growth opportunities, seeking motivated individuals to join their team.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Watertown, United States
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 63.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Immunotherapy, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Oct 2025 | $0 | — | Undisclosed | ↗ |
| SERIES AOther financing | Apr 2024 | $54M | $216M | Cockrell Interests · Ziff Capital Partners · Sandia Holdings · Tanis ventures | ↗ |
Growth signals
Latest recorded traffic for Corner Therapeutics is 890 monthly website visits, down 40.7% over the last three months. Corner Therapeutics's team declined 22.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Bill & Melinda Gates Foundation
Series A4 investors entered at this stage
- CICockrell Interests
- ZPZiff Capital Partners
- SHSandia Holdings
- TVTanis ventures
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Corner Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Corner Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.